Endo International plc – (NASDAQ:ENDP) (TSE:ENL) – Research analysts at Leerink Swann issued their Q3 2018 earnings per share estimates for Endo International in a report issued on Tuesday. Leerink Swann analyst A. Fadia anticipates that the company will post earnings per share of $0.76 for the quarter. Leerink Swann has a “Outperform” rating and a $12.00 price target on the stock. Leerink Swann also issued estimates for Endo International’s Q4 2018 earnings at $0.75 EPS and FY2022 earnings at $2.96 EPS.

Endo International (NASDAQ:ENDP) (TSE:ENL) last issued its quarterly earnings data on Thursday, November 9th. The company reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.85 by $0.06. Endo International had a negative net margin of 126.97% and a positive return on equity of 66.98%. The company had revenue of $786.90 million for the quarter, compared to analysts’ expectations of $794.93 million. During the same quarter in the previous year, the firm posted $1.01 earnings per share. Endo International’s revenue for the quarter was down 11.0% on a year-over-year basis.

Several other brokerages have also recently weighed in on ENDP. Goldman Sachs Group initiated coverage on shares of Endo International in a research note on Thursday, September 28th. They issued a “sell” rating and a $7.00 price objective on the stock. Royal Bank of Canada dropped their target price on shares of Endo International from $9.00 to $8.00 and set a “sector perform” rating on the stock in a report on Friday, November 10th. Guggenheim assumed coverage on shares of Endo International in a report on Tuesday, December 12th. They issued a “neutral” rating and a $8.50 target price on the stock. Cantor Fitzgerald dropped their target price on shares of Endo International from $9.00 to $7.00 and set a “neutral” rating on the stock in a report on Friday, November 10th. Finally, Piper Jaffray Companies restated a “hold” rating and issued a $9.00 target price on shares of Endo International in a report on Sunday, September 17th. Two analysts have rated the stock with a sell rating, sixteen have given a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $11.27.

Shares of Endo International (NASDAQ ENDP) opened at $8.69 on Thursday. The company has a quick ratio of 0.86, a current ratio of 1.08 and a debt-to-equity ratio of 10.78. Endo International has a one year low of $5.77 and a one year high of $17.63. The firm has a market cap of $1,949.53, a price-to-earnings ratio of -0.39, a P/E/G ratio of 3.00 and a beta of 0.59.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Teachers Advisors LLC raised its holdings in shares of Endo International by 1.9% in the 2nd quarter. Teachers Advisors LLC now owns 840,470 shares of the company’s stock worth $9,388,000 after acquiring an additional 15,928 shares during the last quarter. Diamond Hill Capital Management Inc. raised its holdings in shares of Endo International by 46.8% in the 3rd quarter. Diamond Hill Capital Management Inc. now owns 716,670 shares of the company’s stock worth $6,138,000 after acquiring an additional 228,426 shares during the last quarter. TIAA CREF Investment Management LLC raised its holdings in shares of Endo International by 1.6% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 649,535 shares of the company’s stock worth $7,255,000 after acquiring an additional 10,387 shares during the last quarter. Ameriprise Financial Inc. raised its holdings in shares of Endo International by 4.9% in the 2nd quarter. Ameriprise Financial Inc. now owns 581,552 shares of the company’s stock worth $6,497,000 after acquiring an additional 27,414 shares during the last quarter. Finally, Parametric Portfolio Associates LLC raised its holdings in shares of Endo International by 18.7% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 398,099 shares of the company’s stock worth $4,447,000 after acquiring an additional 62,822 shares during the last quarter. Hedge funds and other institutional investors own 93.06% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was first reported by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be accessed at https://www.watchlistnews.com/research-analysts-set-expectations-for-endo-international-plc-s-q3-2018-earnings-endp/1797192.html.

About Endo International

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Earnings History and Estimates for Endo International (NASDAQ:ENDP)

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.